Given that ASXL1, ASXL2 and ASXL3 mutations are invariably heterozygous16, our studies raise the possibility that the truncated versions of ASXL1 mutations in cancers and in Bohring–Opitz syndrome could act as gain-of-function mutations. The gene discussed is ASXL3; the disease is cancer.